Expert hematologist-oncologists review key updates in the treatment of CLL presented at recent conferences and consider their impact on clinical practice.
EP. 2: Chronic Lymphocytic Leukemia: Role of First-Generation BTK InhibitorsJanuary 18th 2023
A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.
EP. 3: Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or ZanubrutinibJanuary 25th 2023
Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.